Stensvold D, Tjønna AE, Skaug EA, Aspenes S, Stølen T, Wisløff U, Slørdahl SA. Strength training versus aerobic interval training to modify risk factors of metabolic syndrome. J Appl Physiol 108: 804-810, 2010. First published January 21, 2010 doi:10.1152/japplphysiol.00996.2009.-Metabolic syndrome is characterized by central obesity, elevated blood pressure, high fasting glucose and triglyceride levels, and low HDL levels. Regular physical activity can improve the metabolic profile and reduce the risks of cardiovascular diseases and premature mortality. However, the optimal training regime to treat metabolic syndrome and its associated cardiovascular abnormalities remains undefined. Fortythree participants with metabolic syndrome were randomized to one of the following groups: aerobic interval training (AIT; n ϭ 11), strength training (ST; n ϭ 11), a combination of AIT and ST (COM; n ϭ 10) 3 times/wk for 12 wk, or control (n ϭ 11). Risk factors comprising metabolic syndrome were evaluated before and after the intervention. Waist circumference (in cm) was significantly reduced after AIT [95% confidence interval (CI): Ϫ2.5 to Ϫ0.04], COM (95% CI: Ϫ2.11 to Ϫ0.63), and ST (95% CI: Ϫ2.68 to Ϫ0.84), whereas the control group had an increase in waist circumference (95% CI: 0.37-2.9). The AIT and COM groups had 11% and 10% increases in peak O2 uptake, respectively. There were 45% and 31% increases in maximal strength after ST and COM, respectively. Endothelial function, measured as flow-mediated dilatation (in %), was improved after AIT (95% CI: 0.3-3), COM (95% CI: 0.3-3), and ST (95% CI:
These data represent the largest reference material of objectively measured VO2peak in healthy men and women age 20-90 yr. Even in people considered to be fit, VO2peak was clearly associated with levels of conventional cardiovascular risk factors.
The nonexercise regression model developed in the present study was fairly accurate in predicting V·O 2peak in this healthy population of men and women. The model might be generalized to other healthy populations and might be a valid tool for a rough assessment of cardiorespiratory fitness in an outpatient setting.
Aerobic fitness, measured as maximal oxygen uptake (VO2max), is a good indicator of cardiovascular health, and a strong predictor of cardiovascular mortality. Biomarkers associated with low VO2max may therefore represent potential early markers of future cardiovascular disease (CVD). The aim of this study was to assess whether circulating microRNAs (miRs) are associated with VO2max-level in healthy individuals. In a screening study, 720 miRs were measured in serum samples from healthy individuals (40–45 yrs) with high (n = 12) or low (n = 12) VO2max matched for gender, age and physical activity. Candiate miRs were validated in a second cohort of subjects with high (n = 38) or low (n = 38) VO2max. miR-210 and miR-222 were found to be higher in the low VO2max-group (p<0.05). In addition, miR-21 was increased in male participants with low VO2max (p<0.05). There were no correlations between traditional risk factors for CVD (blood pressure, cholesterol, smoking habit, or obesity) and miR-21, miR-210 and miR-222. DIANA-mirPath identified 611 potential gene-targets of miR-21, miR-210 and miR-222, and pathway analysis indicated alterations in several important signaling systems in subjects with low VO2max. Potential bias involve that blood was collected from non-fasting individuals, and that 8 performed exercise within 24 h before sampling. In conclusion, we found that miR-210, miR-21, and miR-222 were increased in healthy subjects with low VO2max. The lack of association between these three miRs, and other fitness related variables as well as traditional CVD risk factors, suggests that these miRs may have a potential as new independent biomarkers of fitness level and future CVD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.